Obesity-drug specialists Arena Pharmaceuticals and VIVUS have already launched their products in the United States, but both have struggled to get the green light in the European Union. While the two fight for market share in the U.S., Orexigen Therapeutics , the third major player in this space, announced last week that it has submitted an application with the European Medicines Agency for the approval of its obesity medication Contrave. Orexigen has yet to get its drug approved by the FDA, but could it beat both Arena and VIVUS to the European market? Analysts David Williamson and Max Macaluso discuss this story in the following video.

Incredible growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

The article Can This Obesity-Drug Maker Beat Arena and VIVUS in Europe? originally appeared on Fool.com.

David Williamson owns shares of Facebook. Max Macaluso, Ph.D. owns shares of Apple. The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Investing in Real Estate

Learn the basics of investing in real estate.

View Course »

Add a Comment

*0 / 3000 Character Maximum